Goldfarb Branham LLP is investigating whether certain officers and directors of Genoptix, Inc. (NASDAQ: GXDX) violated state and federal securities laws. Genoptix stock plummeted from $38.79 in April 2010 to $17.19 in June 2010 after the company issued a series of statements about its financial results far below consensus. Concerned shareholders are urged to contact securities lawyer Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.

“According to a class action complaint, the company failed to disclose its significant problems while touting its hematology and oncology testing and diagnostics business,” said securities lawyer Hamilton Lindley. “Those allegations also include that Genoptix failed to disclose its business model was unsustainable due to increased competition, managed care pressures, sales force effectiveness and changing trends at the physician level.”

Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. The firm may be retained without financial obligation or cost to its clients. Genoptix investors who purchased before or between June 31, 2009 and June 15, 2010, and continue to hold their shares, should contact Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.

Copyright Business Wire 2010